Merck (MRK) +3% AH after reporting favorable Phase III trial results for its odnacatib...

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

Merck (MRK) +3% AH after reporting favorable Phase III trial results for its odnacatib osteoporosis drug. The company says it will "begin taking steps to close the trial," and plans to submit the drug for approval by U.S., E.U., and Japanese regulators in 1H 2013. (PR)